Articles

Rituximab induced serum sickness or immune complex deposition disease: case report and desensitisation protocol

BJH - volume 11, issue 2, march 2020

N.C. Granacher MD, T. Eyckmans MD

SUMMARY

The chimeric monoclonal IgG1 antibody directed to CD20 Rituximab is used to treat various haematological malignancies and auto-immune diseases. Serum sickness is a type III hypersensitivity reaction leading to the formation and tissue deposition of immune antibody-antigen complexes. It has been described as a very rare complication of Rituximab treatment, mainly seen in patients treated for auto-immune diseases. We report the case of a patient with Waldenstrom’s macroglobulinaemia whose Rituximab treatment was complicated by documented immune complex deposition or serum sickness. We successfully applied a Rituximab desensitisation protocol, which allowed us to complete treatment.

(BELG J HEMATOL 2020;11(2):75–8)

Read more

P.24 Rare morphologic phenomena in plasma cell dyscrasia: report of two cases

BJH - volume 11, issue Abstract Book BHS, february 2020

K. Kehoe , S. Weekx PhD, S. Vermeiren MD, K. Ver Elst MD, T. Eyckmans MD, C. Schuermans MD, J. Lemmens MD

Read more

PP45 Blood transfusion in Sickle Cell Disease. Retrospective study in ZNA Hospitals (Antwerp)

BJH - 2018, issue Abstract Book BHS, february 2018

T. Eyckmans MD, S. Mahieu , M.P. Emonds MD, PhD, E. Lazarova , P. Vandenberghe MD, PhD, P. Zachée MD, PhD

Read more